Sarclisa Receives New Indication for Relapsed or Refractory Multiple Myeloma

Web Exclusives - FDA Approvals, Select Drug Profiles

On March 31, 2021, the FDA accelerated the approval of a new indication for isatuximab-irfc (Sarclisa; sanofi-aventis), a CD38-directed antibody, in combination with carfilzomib and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy. Isatuximab was initially approved by the FDA in 2020, in combination with pomalidomide and dexamethasone, for adults with relapsed or refractory multiple myeloma who have received ≥2 therapies, including lenalidomide and a proteasome inhibitor.

The FDA approval of isatuximab in combination with carfilzomib and dexamethasone was based on the IKEMA study, a multicenter, multinational, randomized, open-label, 2-arm, phase 3 clinical trial of patients with relapsed or refractory multiple myeloma who had received 1 to 3 lines of therapy. The study included 302 patients who were randomized in a 3:2 ratio to isatuximab plus carfilzomib and dexamethasone or to carfilzomib and dexamethasone.

The main efficacy outcome was progression-free survival (PFS). The median PFS was not reached (NR) in the isatuximab plus carfilzomib and dexamethasone arm versus 20.27 months (95% confidence interval, 15.77-NR) with carfilzomib and dexamethasone alone (P = .003), a 45% risk reduction of disease progression or death with the addition of isatuximab.

The most common (≥20%) adverse reactions with the isatuximab-based combination were upper respiratory tract infection, infusion-related reactions, fatigue, hypertension, diarrhea, pneumonia, dyspnea, insomnia, bronchitis, cough, and back pain. The most common (≥80%) hematology laboratory abnormalities were decreased hemoglobin, decreased lymphocytes, and decreased platelets.

Related Items
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
Web Exclusives published on November 30, 2022 in FDA Approvals
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
Web Exclusives published on November 17, 2022 in FDA Approvals
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
Web Exclusives published on November 17, 2022 in FDA Approvals
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
Web Exclusives published on October 31, 2022 in FDA Approvals
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
Web Exclusives published on October 31, 2022 in FDA Approvals
Last modified: August 30, 2021
Copyright © Engage Healthcare Communications, LLC. All rights reserved.